Mesenchymal stromal cells (MSC), known for their high immune modulatory capacity are promising tools for several cell-based therapies. To better mimic the in vivo situation of MSC interactions with immune cells, we applied an artificial lymph node (ALN)-bioreactor culture system combining a miniaturized perfusion bioreactor with a 3D matrix-based cell culture of immune competent cells forming micro-organoids.
Methods
Rat lymph node cells and allogeneic bone marrow-derived MSCs were seeded in a 20:1 ratio within the agarose matrix of the ALN-reactor. Lymphocytes were pre-incubated with Concanavalin A (ConA) and then co-cultured with MSC in the matrix with additional ConA in the perfusing medium. Live/dead staining showed survival of the co-cultures during the 8-day ALN-reactor run. Paraffin sections of bioreactor matrices were analyzed by proliferating cell nuclear antigen (PCNA)-specific staining to determine MSC proliferation. Immune modulatory capacity was defined by daily analysis of cytokine secretion profiles (TNFα, IFNγ, IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12p40/p70, GM-CSF).
Results
Cytokine peak secretion at day 2 was significantly inhibited by MSCs for TNFα (96.8 ± 4.8%) and IFNγ (88.7 ± 12.0%) in 3D co-cultures. In contrast, other cytokines (IL-1, IL-6, IL-12) were induced. Furthermore, we detected a significantly higher (58.8%) fraction of proliferating MSCs in the presence of immune cells compared to control bioreactors loaded with MSCs only.
Conclusions
In the future, this system might be an excellent tool to investigate the mechanisms of MSC-mediated immune modulation during simulated in vivo conditions.
PittengerM.F., MackayA.M., BeckS.C.Multilineage potential of adult human mesenchymal stem cells.Science.1999; 284(5411): 143–147.
2.
da Silva MeirellesL., ChagastellesP.C., NardiN.B.. Mesenchymal stem cells reside in virtually all post-natal organs and tissues.J Cell Sci.2006; 119(Pt 11): 2204–2213.
3.
HoogduijnM.J., CropM.J., PeetersA.M.Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities.Stem Cells Dev.2007; 16(4): 597–604.
4.
ShiY., HuG., SuJ.Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair.Cell Res.2010; 20(5): 510–518.
5.
DominiciM., Le BlancK., MuellerI.Minimal criteria for defining multi potent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.Cytotherapy.2006; 8(4): 315–317.
6.
SylvesterK.G., LongakerM.T.. Stem cells: review and update.Arch Surg.2004; 139(1): 93–99.
7.
Di NicolaM., Carlo-StellaC., MagniM.Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.Blood.2002; 99(10): 3838–3843.
Le BlancK., TammikL., SundbergB., HaynesworthS.E., RingdénO.. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex.Scand J Immunol.2003; 57(1): 11–20.
10.
KramperaM., GlennieS., DysonJ.Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.Blood.2003; 101(9): 3722–3729.
11.
FangL., LangeC., EngelM., ZanderA.R., FehseB.. Sensitive balance of suppressing and activating effects of mesenchymal stem cells on T-cell proliferation.Transplantation.2006; 82(10): 1370–1373.
12.
DeuseT., StubbendorffM., Tang-QuanK.Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells.Cell Transplant.2011; 20(5): 655–667.
13.
DjouadF., CharbonnierL.M., BouffiC.Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism.Stem Cells.2007; 25(8): 2025–2032.
14.
BernardoM.E., AvanziniM.A., PerottiC.Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute.J Cell Physiol.2007; 211(1): 121–130.
15.
BartmannC., RohdeE., SchallmoserK.Two steps to functional mesenchymal stromal cells for clinical application.Transfusion.2007; 47(8): 1426–1435.
16.
FlemmingA., SchallmoserK., StrunkD., StolkM., VolkH.D., SeifertM.. Immunomodulative efficacy of bone marrow-derived mesenchymal stem cells cultured in human platelet lysate.J Clin Immunol.2011; 31(6): 1143–1156.
17.
JiangX.X., ZhangY., LiuB.Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells.Blood.2005; 105(10): 4120–4126.
18.
BeythS., BorovskyZ., MevorachD.Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness.Blood.2005; 105(5): 2214–2219.
19.
NautaA.J., WesterhuisG., KruisselbrinkA.B., LurvinkE.G., WillemzeR., FibbeW.E.. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting.Blood.2006; 108(6): 2114–2120.
20.
MeiselR., ZibertA., LaryeaM., GöbelU., DäubenerW., DillooD.. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation.Blood.2004; 103(12): 4619–4621.
21.
GeW., JiangJ., ArpJ., LiuW., GarciaB., WangH.. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression.Transplantation.2010; 90(12): 1312–1320.
22.
RenG., ZhaoX., ZhangL.Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression.J Immunol.2010; 184(5): 2321–2328.
23.
WangW., ItakaK., OhbaS.3D spheroid culture system on micropatterned substrates for improved differentiation efficiency of multipotent mesenchymal stem cells.Biomaterials.2009; 30(14): 2705–2715.
24.
KarlsenT.A., MirtaheriP., ShahdadfarA., FloisandY., BrinchmannJ.E.. Effect of three-dimensional culture and incubator gas concentration on phenotype and differentiation capability of human mesenchymal stem cells.J Cell Biochem.2011; 112(2): 684–693.
25.
FrithJ.E., ThomsonB., GeneverP.G.. Dynamic three-dimensional culture methods enhance mesenchymal stem cell properties and increase therapeutic potential.Tissue Eng Part C Methods.2010; 16(4): 735–749.
26.
TrkovS., EngG., Di LiddoR., ParnigottoP.P., Vunjak-NovakovicG.. Micropatterned three-dimensional hydrogel system to study human endothelial-mesenchymal stem cell interactions.J Tissue Eng Regen Med.2010; 4(3): 205–215.
27.
GieseC., DemmlerC.D., AmmerR.A human lymph node in vitro—challenges and progress.Artif Organs.2006; 30(10): 803–808.
28.
GieseC., LubitzA., DemmlerC.D., ReuschelJ., BergnerK., MarxU.. Immunological substance testing on human lymphatic micro-organoids in vitro.J Biotechnol.2010; 148(1): 38–45.
29.
GriffithL.G., SwartzM.A.. Capturing complex 3D tissue physiology in vitro.Nat Rev Mol Cell Biol.2006; 7(3): 211–224.
30.
HaraY., StolkM., RingeJ.In vivo effect of bone marrow-derived mesenchymal stem cells in a rat kidney transplantation model with prolonged cold ischemia.Transpl Int.2011; 24(11): 1112–1123.
31.
HoogduijnM.J., CropM.J., KorevaarS.S.Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin.Transplantation.2008; 86(9): 1283–1291.
HolmesA., BrownR., ShakesheffK.. Engineering tissue alternatives to animals: applying tissue engineering to basic research and safety testing.Regen Med.2009; 4(4): 579–592.
34.
InoueS., PoppF.C., KoehlG.E.Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model.Transplantation.2006; 81(11): 1589–1595.
35.
PoppF.C., EggenhoferE., RennerP.Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate.Transpl Immunol.2008; 20(1-2): 55–60.
36.
RennerP., EggenhoferE., RosenauerA.Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function.Transplant Proc.2009; 41(6): 2607–2611.
37.
HegyiB., KudlikG., MonostoriE., UherF.. Activated T-cells and pro-inflammatory cytokines differentially regulate prostaglandin E2 secretion by mesenchymal stem cells.Biochem-Biophys Res Commun.2012; 419(2): 215–220.
38.
RoelenD.L., van der MastB.J.. in't Anker PS, et al. Differential immunomodulatory effects of fetal versus maternal multipotent stromal cells.Hum Immunol.2009; 70(1): 16–23.
39.
CropM.J., BaanC.C., KorevaarS.S.Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells.Clin ExpImmunol.2010; 162(3): 474–486.
40.
ZinöckerS., VaageJ.T.. Rat mesenchymal stromal cells inhibit T cell proliferation but not cytokine production through inducible nitric oxide synthase.Front Immunol.2012; 3: 62.
41.
KramperaM., CosmiL., AngeliR.Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells.Stem Cells.2006; 24(2): 386–398.
42.
EnglishK., BarryF.P., Field-CorbettC.P., MahonB.P.. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells.Immunol Lett.2007; 110(2): 91–100.
43.
KronsteinerB., WolbankS., PeterbauerA.Human mesenchymal stem cells from adipose tissue and amnion influence T-cells depending on stimulation method and presence of other immune cells.Stem Cells Dev.2011; 20(12): 2115–2126.
44.
BlotnickS., PeoplesG.E., FreemanM.R., EberleinT.J., KlagsbrunM.. T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4 + and CD8 + T cells.Proc Natl Acad Sci U S A.1994; 91(8): 2890–2894.
45.
MerimeeT.J., GrantM.B., BroderC.M., Cavalli-SforzaL.L.. Insulin-like growth factor secretion by human B-lymphocytes: a comparison of cells from normal and pygmy subjects.J Clin Endocrinol Metab.1989; 69(5): 978–984.
